GlassScriptPhysician profile
Robert N Stewart
NPI 1932165073
$10,193.87
in general payments reported to CMS, 2019-2025
38 companies · $2,213 in 2025
The $2,213 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,625 · 2020: $289 · 2021: $886 · 2022: $1,522 · 2023: $1,782 · 2024: $1,877 · 2025: $2,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,792 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,792.26 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,933.70 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,573.38 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,339.37 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Jazz Pharmaceuticals INC. | $602.22 | 2019-2025 | Xywav |
| Mallinckrodt Hospital Products INC. | $449.27 | 2020-2025 | Acthar |
| Insmed, INC. | $364.30 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $321.34 | 2019-2025 | |
| Harmony Biosciences LLC | $320.48 | 2020-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $308.83 | 2019-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $301.76 | 2019-2025 | Zerbaxa, Winrevair, Recarbrio |
| Genentech USA, INC. | $286.54 | 2019-2025 | Xolair |
| Fisher & Paykel Healthcare INC | $217.42 | 2019-2025 | Fisher & Paykel Healthcare |
| Electromed, INC. | $214.05 | 2024-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $196.64 | 2019-2024 | Uptravi, Opsumit |
| United Therapeutics Corporation | $165.02 | 2019-2025 | Tyvaso, Tyvaso |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $142.45 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $132.63 | 2022-2025 | Glassia |
| Novartis Pharmaceuticals Corporation | $130.07 | 2021-2022 | |
| Baxter Healthcare | $115.98 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Amgen INC. | $115.02 | 2022-2025 | Tezspire |
| Sunovion Pharmaceuticals INC. | $92.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.84 | 2019-2024 | |
| Verona Pharma, INC. | $82.57 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $81.92 | 2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $81.19 | 2021-2024 | Yupelri |
| Viatris Specialty LLC | $67.10 | 2025 | Yupelri |
| Mallinckrodt Enterprises LLC | $66.27 | 2019 | |
| Pulmonx Corporation | $65.11 | 2024-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Portola Pharmaceuticals, LLC | $58.31 | 2019 | |
| Gilead Sciences, INC. | $54.25 | 2019-2021 | |
| Tetraphase Pharmaceuticals, INC. | $53.51 | 2019 | |
| Medtronic, INC. | $44.01 | 2023 | Illumisite |
| La Jolla Pharmaceutical Company | $42.30 | 2019-2025 | Giapreza |
| Pfizer INC. | $34.45 | 2022-2024 | |
| Aerin Medical INC. | $16.74 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.74 | 2021 | |
| Monaghan Medical Corporation | $12.45 | 2019 | |
| Ceribell, INC. | $5.96 | 2023 | Ceribell Rapid Response Eeg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.